Closeup of anonymous male doctor hand holding an ampule of medicine with diabetes word (Photo by Creativa Images from Shutterstock.com).

by Ivan Couronne

On a frosty January morning in a Minneapolis suburb, Abigail Hansmeyer leaves her car engine running and takes out a brown paper bag carrying needles and a vial, handing it over to its recipient in an anonymous shopping center parking lot.

The exchange is technically illegal, but these aren’t illicit drugs.

Instead, the vial contains insulin: A medicine that has since its discovery in the 1920s transformed a diagnosis of diabetes from a swift death sentence to a manageable disease.

Yet its price has sky-rocketed in the US over the past decade, creating informal networks of people who build up stockpiles and give to others what they don’t need themselves.

“Thank you so much,” says Annette Gentile, 52, as she takes the bag from Hansmeyer, checking the labels and doses. “I’ve been on a roller coaster in the last few days,” she adds, because of her elevated blood sugar levels.

Gentile doesn’t live in abject poverty. She receives a monthly disability allowance of $1,200 and has public health insurance. Crucially, however, that insurance does not cover prescription medicine.

The contents of the bag she just received, which will keep her going for a month, would cost her about a thousand dollars at a pharmacy. “I purely rely on donations,” she says.

Her 29-year-old benefactor Hansmeyer is unemployed and has type 1 diabetes, a chronic condition that appears in childhood where the pancreas produces little or no insulin, the hormone that lets sugar enter cells to produce energy.

People who have it need to inject themselves with insulin several times a day for the rest of their lives.

Both women are part of a group of diabetics who connect with each over Facebook or text messages to hand out or receive their prized medication, free of cost, sometimes using code words like “lifewater” to evade detection.

Nearly all of the stock that circulates comes from the relatives of patients who died.

For President Donald Trump’s rivals in the Democratic party, who begin their primary contests on Monday in Iowa, there are few scandals greater than the price of insulin: The epitome of pharmaceutical price-gouging that blights the US health care system.

“We’re not poor,” says Hansmeyer. Her husband works and has started a small business, Abigail has her own car, and the couple live in a house that pet dogs and rabbits also call home.

But her husband’s employer doesn’t subsidize its workers health insurance. Not poor enough to qualify for state insurance, and not rich enough to buy their own, the couple gave up looking in January.

They joined the ranks of the 27.5 million Americans without coverage, praying that no calamity befell them.

“My entire adult life I’ve gone in and out of rationing my insulin,” Hansmeyer tells AFP.

A few years ago, when she won a battle against her then insurer for an insulin pump, a computerized device that continuously releases the right amount of the hormone, she remembers crying with happiness.

Death of a child

Hansmeyer acts as a go-between for her community of Minneapolis area diabetics, connecting those in need with those who have. And one of her major sources is a refrigerator in the basement of a house belonging to one Nicole Smith-Holt.

Smith-Holt opens its door to reveal a treasure trove: Dozens of vials of insulin, and a large stock of syringes, test strips and other supplies. She guesses its value at around $50,000.

“It is strictly illegal,” she says.

Selling or even giving away prescription medicine is technically a minor crime. But for Smith-Holt, it’s a cause that is devastatingly close to her heart.

“We don’t need another Alec,” she says, about her late son, who died in June 2017.

Alec Raeshawn Smith was covered by his mother’s insurance until he turned 26, the age up to which insurers are obliged by an Obama-era law to allow adult children to remain covered by their parent’s plans.

After crossing that threshold, he found himself unable to afford his own insurance on his meager salary as a restaurant worker.

He died 27 days after his insurance lapsed from diabetic ketoacidosis as a result of a lack of insulin.

There was not a drop of insulin to be found in his apartment, said Smith-Holt, but there was evidence her son had tampered with his insulin pens to try squeeze out the last bit.

“I think until I take my last breath I’ll feel a sense of guilt in some sort of way,” said Smith-Holt. “I wish he would have asked for help.”

The death of her son, who was himself a father, transformed Smith-Holt into an activist. One day she’s on television, the next she’s lobbying local politicians, or protesting outside a pharmaceutical company.

O Canada

Further to the north, diabetics can look to providers on the right side of the law but the wrong side of the border: Canadian pharmacies.

Unlike the US, Canada caps the price of insulin. Every three months, alone or with others, 47-year-old Travis Paulson makes the two hour drive from Eveleth in northern Minnesota to Fort Frances in Canada’s Ontario province, crossing the Rainy River to buy his insulin without prescription.

Customs agents don’t bother him so long as his supply is less than three months’ worth.

His insurance is excellent as far as doctor visits go, but only pays half the price of medicines.

He pulls out two almost identical vials of insulin: one is labeled NovoLog and costs $345 in the US, with his insurance leaving him responsible for half the bill.

The Canadian vial is sold under the brand name NovoRapid, and costs about $25. The math isn’t hard.

“It’s pharmaceutical greed. It’s greed is all it is, simple as that,” he says.

A Bernie Sanders sticker on his fridge shows off Paulson’s support for the self-professed democratic socialist, who has vowed to cut drug costs in half.

But even that might not be enough to reduce the appeal of his Canadian road trips.

– AFP

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments
You May Also Like

请员工收拾 马国《前锋报》走过八十载正式结业

马来西亚巫统喉舌报《马来西亚前锋报》(Utusan Malaysia)自今年8月传出面对经济困境的消息后,正式公布将于今天内停止营业。 《前锋报》出版商马国前锋报集团今天发出内部通知书,向所有员工宣布公司董事局于周一(10月7日)做出的决定,即批准债权人提出的自愿清盘计划,并且委任UHY Advisory KL担任临时清盘师。 有关的通告由《前锋报》执行主席Datuk Abd. Aziz Sheikh Fadzir 签署后发出,通告中显示今天将是员工们的最后一个工作日,而他们的聘约将于2019年10月31日结束。 通告上写道,该集团自2018年5月开始面对经济困境,虽然采取许多措施来扭转局势,包括指让该集团旗下约700名雇员接受了自愿离职计划(VSS)、脱售一些资产等。 “但是随着《Utusan…

【武汉冠状病毒】创新高 本日新增病例达54起

我国今日新增病例创新高,增加了54起武汉冠状病毒(Covid-19)确诊病例,其中包括48起为入境病例。 卫生部发文告指出,48起入境病例中,其中一位病患是短期入境患者。 剩余的六起病例患者目前并无任何旅行记录,也与先前的案件无关,当局目前尚在追踪与患者有关的近接触者。 这也导致我国的累积病例达到了509起,而其中15名病危患者需待在加护病房。 此外,有8名患者已经痊愈出院,让我国痊愈病例达到了152起。 3月23日公布确诊病例简表 备注:NCID(国家传染病中心);WP(工作准证持有者);LTP(长期准证持有者) 病例 确诊 日期 入住 医院…

【冠状病毒19】和其他病例无关 孟籍工作证件持有者为唯一社区病例

昨日(9月20日)新增的18起冠状病毒19确诊病例,病患全都没有出现症状,且只有一起社区病例。 据卫生部文告指出,唯一的新增社区病例是一名29岁的孟加拉籍工作证件持有者,暂时确定和其他病例没有关联。 昨日的新增病例中,有四起入境病例,他们分别来自德国、菲律宾和伊朗。 来自德国的是一名学生证持有者,他于本月9日入境我国;来自菲律宾的是一名工作证和一名工作准证持有者,于本月8日入境;而来自伊朗的是一名眷属准证持有者,于本月15日入境。他们在入境后履行14天居家通知时,进行冠病检测时证实被感染。 新增病例中有13起来自客工宿舍,其中有五名患者已被隔离,剩余的八名患者则是在接受当局监控监测时确诊的。 昨日并没有新增的感染群体,但是在现有的刘个感染群内曲线了新病例。 截至昨日,我国已经累计了5万7576起确诊病例,康复人数累计了5万7181个,累计死亡人数保持在27人。出院或离开社区隔离设施的人数达39人,目前仍有30人住院。